Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.30
CYTX's Cash to Debt is ranked higher than
50% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CYTX: 0.30 )
CYTX' s 10-Year Cash to Debt Range
Min: 0.3   Max: No Debt
Current: 0.3

Equity to Asset -0.10
CYTX's Equity to Asset is ranked higher than
52% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CYTX: -0.10 )
CYTX' s 10-Year Equity to Asset Range
Min: -0.83   Max: 0.94
Current: -0.1

-0.83
0.94
F-Score: 2
Z-Score: -17.19
M-Score: -4.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -510.96
CYTX's Operating margin (%) is ranked higher than
61% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CYTX: -510.96 )
CYTX' s 10-Year Operating margin (%) Range
Min: -3958.33   Max: -68.58
Current: -510.96

-3958.33
-68.58
Net-margin (%) -571.53
CYTX's Net-margin (%) is ranked higher than
60% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. CYTX: -571.53 )
CYTX' s 10-Year Net-margin (%) Range
Min: -3620.2   Max: -30.65
Current: -571.53

-3620.2
-30.65
ROE (%) -84660.57
CYTX's ROE (%) is ranked lower than
53% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CYTX: -84660.57 )
CYTX' s 10-Year ROE (%) Range
Min: -803.69   Max: -15.07
Current: -84660.57

-803.69
-15.07
ROA (%) -111.21
CYTX's ROA (%) is ranked higher than
53% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. CYTX: -111.21 )
CYTX' s 10-Year ROA (%) Range
Min: -138.62   Max: -7.8
Current: -111.21

-138.62
-7.8
ROC (Joel Greenblatt) (%) -2796.98
CYTX's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. CYTX: -2796.98 )
CYTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1689.33   Max: -173.31
Current: -2796.98

-1689.33
-173.31
Revenue Growth (3Y)(%) -7.80
CYTX's Revenue Growth (3Y)(%) is ranked higher than
73% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CYTX: -7.80 )
CYTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 97.2
Current: -7.8

0
97.2
EBITDA Growth (3Y)(%) -16.40
CYTX's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CYTX: -16.40 )
CYTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.3   Max: 37.5
Current: -16.4

-27.3
37.5
EPS Growth (3Y)(%) -13.40
CYTX's EPS Growth (3Y)(%) is ranked higher than
72% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CYTX: -13.40 )
CYTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -41.5   Max: 102.7
Current: -13.4

-41.5
102.7
» CYTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CYTX Guru Trades in Q4 2013

Paul Tudor Jones 11,026 sh (New)
Jim Simons 46,331 sh (New)
» More
Q1 2014

CYTX Guru Trades in Q1 2014

Paul Tudor Jones 14,433 sh (+30.9%)
Jim Simons Sold Out
» More
Q2 2014

CYTX Guru Trades in Q2 2014

Paul Tudor Jones 14,633 sh (+1.39%)
» More
Q3 2014

CYTX Guru Trades in Q3 2014

Jim Simons 475,131 sh (New)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-09-30 Sold Out $2.1 - $2.82 $ 0.53-79%0
John Burbank 2012-12-31 New Buy$2.58 - $4.44 $ 0.53-86%18450
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 5.30
CYTX's P/S is ranked higher than
89% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. CYTX: 5.30 )
CYTX' s 10-Year P/S Range
Min: 3.7   Max: 43.94
Current: 5.3

3.7
43.94
EV-to-EBIT -1.77
CYTX's EV-to-EBIT is ranked lower than
55% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTX: -1.77 )
CYTX' s 10-Year EV-to-EBIT Range
Min: -16   Max: -1.3
Current: -1.77

-16
-1.3
Current Ratio 1.01
CYTX's Current Ratio is ranked higher than
51% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CYTX: 1.01 )
CYTX' s 10-Year Current Ratio Range
Min: 1.01   Max: 26.46
Current: 1.01

1.01
26.46
Quick Ratio 0.66
CYTX's Quick Ratio is ranked higher than
51% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CYTX: 0.66 )
CYTX' s 10-Year Quick Ratio Range
Min: 0.66   Max: 24.95
Current: 0.66

0.66
24.95

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
CYTX's Price/Median PS Value is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CYTX: 0.40 )
CYTX' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 3.23
Current: 0.4

0.44
3.23
Earnings Yield (Greenblatt) -55.40
CYTX's Earnings Yield (Greenblatt) is ranked higher than
51% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. CYTX: -55.40 )
CYTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -55.4   Max: 0
Current: -55.4

-55.4
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XMPA.Germany,
Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
5-year lows: Fuel Systems Solutions Inc, Dawson Geophysical Co, Forest Oil Corp, and Cytori Therapeu Sep 08 2014 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
cooldecency99 note on CYTX May 01 2010 
creiter note on CYTX Jan 03 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Reports 2nd Quarter 2009 Financial Results Aug 10 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 6,600 Shares May 20 2009 

More From Other Websites
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 22 2014
8:04 am Cytori Therapeuticsand BARDA amend contract option to accelerate the advancement of a... Dec 21 2014
Cytori and BARDA Amend Contract Option to Accelerate the Advancement of a Thermal Burn Injury... Dec 19 2014
Cytori and BARDA Amend Contract Option to Accelerate the Advancement of a Thermal Burn Injury... Dec 19 2014
Nasdaq stocks posting largest volume increases Dec 18 2014
Cytori to Host an Informational Session on Its Planned U.S. STAR Pivotal Trial With Principal... Dec 18 2014
Cytori to Host an Informational Session on Its Planned U.S. STAR Pivotal Trial With Principal... Dec 18 2014
Cytori to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco Dec 17 2014
Cytori to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco Dec 17 2014
FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma Dec 10 2014
BUZZ-U.S. Stocks on the Move-Linn Energy, Cytori, United Continental Dec 10 2014
FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma Dec 10 2014
Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing Dec 05 2014
Cytori Therapeutics' Investor Presentation Now Available for On-Demand Viewing Dec 05 2014
Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy Dec 04 2014
Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy Dec 04 2014
Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy Dec 04 2014
Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com Dec 02 2014
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 26 2014
Cytori Announces Promising Results in a Feasibility Trial of Cytori Cell Therapy in Conjunction with... Nov 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK